Impairment of Bone Mineral Density in Pituitary Thyrotropin-Secreting Adenomas: A Retrospective, Controlled Study
Authors' conclusion
TSHoma patients exhibit significant BMD deficits compared to euthyroid controls. Surgery effectively reduces BTMs while stabilizing BMD, preventing further deterioration rather than restoring bone density.
Study context
- Population
- Patients with thyroid-stimulating hormone/thyrotropin (TSH)-secreting pituitary adenomas (TSHomas) who underwent bone mineral density (BMD) tests85 TSHoma reviewed
- Participants
- 71 vs 71
- Exposure
- TSHoma patients vs euthyroid controls
- TSHoman = 71
- Euthyroid controlsn = 71reference
- Outcome
- BMD
- Follow-up
- Baseline
Methodological detailsmatched by age, sex and BMI
- Matched by age, sex and BMI
Main finding
As reported in the abstract
Reduction
12.4%
P < 0.001
lumbar spine: 1.06 ± 0.19 vs 1.21 ± 0.14 g/cm²
Reduction
8.5%
P < 0.001
femoral neck: 0.86 ± 0.14 vs 0.94 ± 0.11 g/cm²
Reduction
14.8%
P < 0.001
total hip: 0.86 ± 0.13 vs 1.01 ± 0.12 g/cm²
Observational data: associations, not effects.
Further findings
Baseline bone turnover markers (BTMs)
- Elevated osteoblastic marker: P1NP (ng/mL)
- 108 [60, 202]
- Elevated osteoclastic marker: β-CTX (ng/mL)
- 0.84 [0.62, 1.30]
Correlation of FT3 with BTMs
- FT3 vs alkaline phosphatase
- r = 0.45, P = .005
- FT3 vs β-CTX
- r = 0.61, P < .001
- FT3 vs P1NP
- r = 0.73, P = .004
- Strong positive correlations
BTMs after tumor resection · pre- to postoperative
- Alkaline phosphatase decreased (U/L)
- 91 [74.25, 119.5] to 71 [68, 94], P = .003
- β-CTX decreased (ng/mL)
- 0.75 [0.57, 0.94] to 0.22 [0.21, 0.45], P = .008
Postoperative BMD
- Stabilization with nonsignificant improvements at all measured skeletal sites
Original publication
Impairment of Bone Mineral Density in Pituitary Thyrotropin-Secreting Adenomas: A Retrospective, Controlled Study. Endocr Pract. Published 30 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →